Incubate’s John Stanford on why MFN’s first casualty is the moonshot — and why cancer, Alzheimer’s, and rare disease bear the cost.
|Articles|November 1, 2017
Talking Pharma Reputation with Bioethics International
Author(s)Michelle Maskaly
Jennifer Miller talks about about pharma's reputation problem.
Advertisement
Pharm Exec Editor, Michelle Maskaly sat down with Jennifer Miller, the founder & board president of Bioethics International. In this brief video, Jennifer talks about pharma's reputation.
Advertisement
Related to this article
Incubate’s John Stanford on why MFN reduces pharma’s appetite for biotech acquisitions — and why that cedes ground to China.
Incubate’s John Stanford on why MFN deals are voluntary in name only — and why the leverage looks a lot like the IRA’s 95% excise tax.
Incubate’s John Stanford on why MFN hits mid-sized pharma harder — fewer products to absorb margin hits and less access to cheap capital.
Fox Rothschild's Marc Wagner on why domestic manufacturing reduces drug shortage risk — and why FDA inspection efficiency is as important as supply chain resilience.
Fox Rothschild's Marc Wagner on how 503A pharmacies and 503B outsourcing facilities fill drug supply gaps — from COVID injectables to GLP-1s.
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: Gilead Acquires Oral IL-23R Inhibitor From PepStar for $1.275 Billion, Zymeworks Licenses DLL3-Targeting T Cell Engager to Roche
2
Treasury Proposes Rules Adding Biotechnology to Outbound Investment Security Program
3
FDA Approves Hibsago (Bepirovirsen) for Chronic Hepatitis B
4
MFN Is an Offer Pharma Can’t Refuse
5